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function. Cold crystalloid cardioplegia obviously
reduces metabolic need, but this is not sufficient to pro-
vide adequate protection.3 Warm reperfusion, which
permits immediate recovery of cardiac function,
improves myocardial protection induced by cold crys-
talloid cardioplegia.4 There are 3 levels of temperature
commonly used in intermittent antegrade blood cardio-
plegia: (1) cold (8°C); (2) tepid (29°C); and (3) warm
(37°C). Given the 21°C spread and the metabolic
changes that can occur between cold (8°C) and tepid
(29°C) cardioplegia, we thought it worthwhile to test a
temperature halfway between the cold and tepid levels:
20°C blood cardioplegia. The aim of this study was to
test the quality of myocardial protection provided by
intermediate lukewarm (20°C) cardioplegia by compar-
ing it with cold and warm cardioplegia. To the best of
our knowledge, no study to date has reported the quali-
ty of myocardial protection provided by blood cardio-
plegic solution delivered at 20°C. We designed a
prospective randomized study by using 3 different tem-
C ardiac troponin I has been shown to be a sensitiveand specific marker of ischemia during heart opera-
tions,1 and we have used it to compare different meth-
ods of myocardial protection.2-4 Effective myocardial
protection is a compromise between two opposing
strategies: (1) reducing metabolic need by cardiac arrest
and lower myocardial temperature and (2) increasing
myocardial temperature during cardiac arrest to
increase the chances of immediate recovery of cardiac
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peratures of blood cardioplegia: cold, from 6°C to 8°C;
intermediate lukewarm, from 18°C to 20°C; and warm,
from 35°C to 37°C. Delivery was intermittent and ante-
grade, cardiopulmonary bypass was conducted at 37°C,
and a hot shot was performed before aortic unclamping
in all 3 groups. Cardiac troponin I release was the cri-
terion used to evaluate the adequacy of myocardial pro-
tection.
Patients and methods
Patient selection. After approval by our institutional
review board, informed consent was obtained from all eligi-
ble patients. One hundred thirty-five consecutive patients
(111 men and 24 women; mean age, 65 ± 9 years) scheduled
for first elective coronary artery bypass grafting were
enrolled in a prospective randomized trial comparing cold
(6°C-8°C), intermediate lukewarm (18°C-20°C), and warm
(35°C-37°C) blood cardioplegia. Not included in this study
were patients with aortic incompetence, patients requiring
only one distal anastomosis, patients with an ejection fraction
below 0.30, patients undergoing reoperation, and patients
with concomitant heart valve disease or unstable angina. The
study took place over a 9-month period, during which 216
patients were not included in the study for the reasons given
above. Among these 216 patients, 71 requiring isolated coro-
nary artery bypass grafting did not satisfy inclusion criteria.
An independent data manager was responsible for supervis-
ing patient registration. A randomization list of consecutive
random treatment assignments had been prepared in ad-
vance. This randomization list was transferred to a series of
sealed envelopes, each containing the name of the next treat-
ment on a card. Envelopes were opened sequentially as each
patient entered the trial (ie, entered the operating room).
Coronary artery stenoses causing a loss of 70% or more of
the cross-sectional area were considered to be significant.
For the left main coronary artery, a loss of 50% was consid-
ered significant.
Operative technique. Cannulation for cardiopulmonary
bypass was carried out in the usual fashion with a single-stage
venous cannulation technique and active normothermia
(37°C). Consequently, the patients were rewarmed immedi-
ately after the onset of the cardiopulmonary bypass. The left
ventricle was vented by a catheter introduced through the
right superior pulmonary vein. The route of delivery was
exclusively antegrade in all groups. Cardioplegic solution
was injected into the aortic root immediately after aortic
crossclamping and until cardiac arrest was achieved with a
minimal amount of 700 mL. A dose of 400 mL was reinject-
ed into the aortic root after each distal anastomosis, with the
exception of the last anastomosis. No additional doses of car-
dioplegic solution were given through the vein grafts after
completion of the distal anastomosis in any group. Proximal
graft anastomoses to the aorta were performed with partial
occlusion of the ascending aorta.
Cardioplegia groups. Cardioplegic solution was adminis-
tered with the Dideco D514 delivery set (Dideco Inc,
Mirandola, Italy), which mixes and cools or rewarms oxy-
genated blood with a modified St Thomas’ Hospital solution,
to which 4 g/L potassium was added in a 3:1 dilution. The
temperature of cardioplegic solution depended on the group:
6°C to 8°C in the cold group, 18°C to 20°C in the intermedi-
ate lukewarm group, and 35°C to 37°C in the warm group. A
1-minute hot shot composed exclusively of 37°C oxygenated
blood with a constant flow rate of 200 mL/min was per-
formed immediately after the last distal anastomosis, once the
thoracic artery or arteries were unclamped. 
Measurements of cardiac marker proteins. Serial
venous blood samples were drawn just before cardiopul-
monary bypass and after aortic unclamping at 6, 9, 12, and 24
hours and daily thereafter for 5 days. Cardiac troponin I con-
centrations were measured by using a specific immunoenzy-
mometric assay developed by Sanofi Diagnostics Pasteur
(Marne-la-Coquette France). Each standard cardiac troponin
I or test sample was incubated with monoclonal antibody 8E1
for 15 minutes. After washing, enzyme activity was measured
after the addition of a substrate (tetramethylbenzydine). The
reaction was stopped by adding H2SO4, and the absorbance
was read at 450 nm on the status spectrophotometer. Creatine
kinase isoenzyme MB (CK-MB) was measured at hour 6.
Electrocardiogram. A 12-lead electrocardiogram (ECG)
was recorded preoperatively, at 2 hours, and then daily post-
operatively. ECG diagnosis criteria for perioperative myocar-
dial infarction (MI) were new Q waves of greater than 0.04
ms and a reduction in R waves of greater than 25% in at least
2 leads. Cardiac troponin I diagnosis criteria for perioperative
MI were cardiac troponin I peak concentrations of greater
than 3.7 µg/L and cardiac troponin I concentrations of greater
than 3.1 µg/L at 12 hours or greater than 2.5 µg/L at 24 hours,
as determined by Mair and colleagues.5
Statistical analysis. Sample sizes were calculated for a 2-
sided significance level (α = .05 and power 1-β = .8) to detect
a difference of 0.4 µg/L in cardiac troponin I concentration
between groups. The standard deviation of measurements of
cardiac troponin I was based on a previous study.1 The num-
ber of subjects required in each group was 40. Statistical
analysis was performed with BMDP statistical software
(BMDP Corp, Los Angeles, Calif). One-way analysis of
covariance with repeated measures (BMDP 5V) was per-
formed to test the effect of the type of cardioplegia and time
on cardiac troponin I concentration. Categoric data and quan-
titative variables were compared by using the χ2 test and 1-
way analysis of variance, respectively. Values are expressed
as means ± standard deviation.
Results
With regard to the preoperative and operative data
(Table I), randomization produced 3 equivalent groups.
Two (1.5%) patients died within 30 days. Both were
from the intermediate lukewarm group. One of them
died of perioperative MI at hour 4, and the other died
of a postoperative stroke at day 28. One patient from
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the cold group had a transient postoperative stroke.
Two patients in the 20°C group required an intra-aortic
balloon pump. One of them was the patient who died of
perioperative MI at hour 4. One patient randomized in
the cold group was mistakenly given warm cardiople-
gia. This patient was analyzed in the group to which he
had been randomized. The blood samples of two
patients in the warm group and one patient from the
intermediate lukewarm group (dead at hour 4) were not
drawn. Age, sex, preoperative ejection fraction, body
surface area, the average number of distal anastomoses
per patient, crossclamping time, and cardiopulmonary
bypass time were equivalent in all groups. At least one
thoracic artery was used in all patients. Sequential
grafts were performed in 6 patients in the cold group, 8
patients in the intermediate lukewarm group, and 4
patients in the warm group (P = .5). The repartition of
coronary angiographic data did not differ from one
group to the other (Table II). Fig 1 shows the time
course of cardiac troponin I concentration according to
the type of cardioplegia. Cardiac troponin I concentra-
tion was significantly higher in the cold group at hours
6, 9, and 12 (1.86 ± 0.97 µg/L at hour 6, 1.20 ± 0.61
µg/L at hour 9, and 0.80 ± 0.47 µg/L at hour 12) than
in the intermediate lukewarm group (1.23 ± 0.55 µg/L
at hour 6, 0.80 ± 0.36 µg/L at hour 9, and 0.51 ± 0.23
Table I. Patient profile by group
Intermediate 
Cold group lukewarm group Warm group 
Variable (n = 45) (n = 45) (n = 45) P value
Mean age (y) 64 ± 9 66 ± 9 64 ± 9 .4
Ejection fraction 0.55 ± 0.1 0.53 ± 0.1 0.55 ± 0.1 .4
Body surface area (m2) 1.86 ± 0.18 1.85 ± 0.15 1.86 ± 0.16 .6
Anterior preoperative MI (n) 9 9 8 .95
Inferior preoperative MI (n) 15 14 15 .95
Distal anastomoses per patients (n) 2.5 ± 0.7 2.5 ± 0.6 2.3 ± 0.6 .15
LITA used (n) 12 14 15 .8
LITA and RITA used (n) 33 31 30 .8
Saphenous vein grafts (n) 27 30 25 .5
Sequential grafts (n) 6 8 4 .5
Crossclamp time (min) 38 ± 10 37 ± 13 35 ± 12 .6
Pump time (min) 60 ± 15 61 ± 19 56 ± 16 .4
Amount of crystalloid cardioplegic solution (mL) 360 ± 100 410 ± 150 370 ± 160 .15
Postoperative peak CK-MB (IU/L) 20 ± 8 17 ± 10 17 ± 13 .5
Total amount of CTnI (µg) 4.7 ± 2.3 3.4 ± 2.0 3.1 ± 2.7 .007
Postoperative stroke (n) 1 1 0 .6
30-day mortality (n) 0 2 0 .1
Where applicable, values are expressed as mean ± standard deviation. MI, Myocardial infarction; LITA, left internal thoracic artery; RITA, right internal thoracic
artery; CTnI, cardiac troponin I.
Table II. Angiographic data
Intermediate 
Variable Cold group lukewarm group Warm group P value
LMCA stenosis ≥50% .3
No 32 38 34
Yes 13 7 11
LMCA stenosis ≥50% .2
With normal RCA 7 2 8
With diseased RCA 6 5 3
No. of diseased vessels* .7
1 1 3 3
2 11 10 13
3 20 25 18
LMCA, Left main coronary artery; RCA, right coronary artery. 
*Stenosis of left main coronary artery excluded.
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µg/L at hour 12; P < .001 for the pattern) or the warm
group (0.89 ± 0.50 µg/L at hour 6, 0.73 ± 0.60 µg/L at
hour 9, and 0.54 ± 0.62 µg/L at hour 12; P < .001 for
the pattern). Cardiac troponin I concentration was sig-
nificantly higher in the intermediate lukewarm group at
hour 6 (1.23 ± 0.55 µg/L) than in the warm group (0.89
± 0.50 µg/L; P = .005). The total amount of cardiac tro-
ponin I released, estimated by the area under the corre-
sponding curve (Fig 1), was significantly higher in the
cold group (4.7 ± 2.3 µg) than in the intermediate luke-
warm group (3.4 ± 2.0 µg; P = .008) or the warm group
(3.1 ± 2.7 µg, P = .005). The total amount of cardiac
troponin I released tended to be higher in the interme-
diate lukewarm group (3.4 ± 2.0 µg) than in the warm
group (3.1 ± 2.7 µg, P = .60). Spontaneous return to
sinus rhythm after aortic unclamping was significantly
higher in the warm group (93%) than in the intermedi-
ate lukewarm group (75%, P = .02) or the cold group
(9%, P < .001). Spontaneous return to sinus rhythm
after aortic unclamping was related to a lower release
of cardiac troponin I. The total amount of cardiac tro-
ponin I released in patients with spontaneous return to
sinus rhythm after aortic unclamping was significantly
lower (3.0 ± 1.75 µg) than in patients requiring electri-
cal defibrillation (4.9 ± 2.9 µg, P < .001), irrespective
of the group. Cardiac troponin I concentrations at hours
6, 9, 12, and 24 were significantly lower in patients
with spontaneous return to sinus rhythm after unclamp-
ing of the aorta (1.0 ± 0.6 µg/L, 0.7 ± 0.4 µg/L, 0.5 ±
0.3 µg/L, and 0.3 ± 0.2 µg/L, respectively) than in
patients requiring electrical defibrillation (1.7 ± 0.9
µg/L, 1.1 ± 0.6 µg/L, 0.8 ± 0.6 µg/L, and 0.5 ± 0.4
µg/L; P < .001 for the pattern; Fig 2).
In the intermediate lukewarm group, one patient who
died had ECG evidence of perioperative MI. One
patient in the warm group had cardiac troponin I evi-
dence of perioperative MI. Thirty-seven patients in the
cold group, 33 in the intermediate lukewarm group, and
36 in the warm group required no inotropic support (P
= .6). Three patients from the cold group, 7 from the
intermediate lukewarm group, and 9 from the warm
group (P = .2) received either dopamine hydrochloride
(3-5 µg · kg–1 · min–1) or dobutamine (3-5 µg · kg–1 ·
min–1). Five patients from the cold group, 5 from the
intermediate lukewarm group (including the 2 patients
who required an intra-aortic balloon pump), and none
from the warm group (P = .07) received epinephrine
(0.2-0.5 µg · kg–1 · min–1). The total amount of cardiac
troponin I released was higher in patients requiring
inotropic support than in patients not requiring inotro-
pic support (4.5 ± 2.6 µg vs 3.6 ± 2.4 µg, P = .08). CK-
MB concentration at hour 6 was equivalent in all
groups.
Discussion
Most of the advantages of blood cardioplegia stated
by Barner6 are temperature dependent; they occur at
37°C and are probably less effective when the temper-
ature is lowered. On the other hand, myocardial
requirements increase as the temperature rises.
Therefore the question arises as to what is the best
compromise.
Fig 1. Time course of cardiac troponin I concentration
according to type of cardioplegia. Cardiac troponin I concen-
tration was significantly higher in the cold group at hours 6,
9, and 12 than in the intermediate lukewarm or the warm
group. Cardiac troponin I concentration was significantly
higher in the intermediate lukewarm group at hour 6 than in
the warm group.
Fig 2. Time course of cardiac troponin I concentration
according to cardiac rhythm recovery after aortic unclamp-
ing. Cardiac troponin I concentrations at hours 6, 9, 12, and
24 were significantly lower in patients with spontaneous
return to sinus rhythm after unclamping of the aorta than in
patients requiring electrical defibrillation.
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Three levels of temperature are commonly used in
intermittent antegrade blood cardioplegia: (1) cold
(8°C); (2) tepid (29°C); and (3) warm (37°C). Cold car-
dioplegia has been shown to impair mitochondrial state
3 respiration,7 which is probably related to the delay of
cardiac functional recovery.8 Because we do not know
at what temperature cardiomyocyte mitochondrial dys-
function begins to appear, an intermediate lukewarm
cardioplegic solution needed to be tested. Given the
21°C spread and the metabolic changes that can occur
between cold (8°C) and tepid (29°C) cardioplegia, we
thought it worthwhile to test a temperature halfway
between the cold and tepid levels. Intermediate luke-
warm cardioplegia seemed likely to provide better
myocardial protection than cold cardioplegia and, per-
haps, warm cardioplegia. Buckberg and colleagues,9
looking at oxygen consumption in canine hearts, sug-
gested that cardioplegia need not be cold to be effective.
However, lowering the temperature reduces oxygen
consumption, and if mitochondrial energy generation is
not impaired at 20°C, or at least less so than at 8°C, the
result may be better myocardial protection.
Cold intermittent antegrade cardioplegia has been the
benchmark for myocardial protection.10 On the other
hand, many studies11,12 have demonstrated the interest
of using antegrade intermittent warm blood cardiople-
gia. We therefore chose cold and warm cardioplegia to
evaluate intermediate lukewarm cardioplegia. As tepid
(29°C) and warm cardioplegia were likely to provide
similar myocardial protection because their tempera-
tures are very close, we thought that a comparison
between 20°C and tepid cardioplegia was unnecessary.
Two points led us to this opinion. First, Buckberg and
colleagues’9 results, as stated above, suggest that the
difference in oxygen consumption should be very small
when the temperature falls from 37°C to 29°C. This
was confirmed by Hayashida and colleagues,7 who
showed that there was no significant difference in oxy-
gen extraction and lactate or acid production between
warm and tepid antegrade cardioplegia. Second, again
because of the proximity of the temperatures, mito-
chondrial respiration preservation should be equivalent
with both techniques, as confirmed by Hayashida and
colleagues8 in a second study.
Cardiac troponin I is a specific marker of myocardial
damage.13 We have already performed studies showing
(1) the sensitivity of cardiac troponin I to myocardial
ischemia1,14 and (2) the interest of using cardiac tro-
ponin I to compare different methods of myocardial
protection in cardiac surgery.2-4 The aim of our present
prospective randomized study was to test the quality of
myocardial protection provided by intermediate luke-
warm cardioplegia by comparing it with cold and warm
cardioplegia and by using cardiac troponin I as the cri-
teria for evaluating the adequacy of myocardial protec-
tion. To answer this question, we designed a study
including 3 temperatures of blood cardioplegia deliv-
ery: cold, 6°C to 8°C; intermediate lukewarm, 18°C to
20°C; and warm, 35°C to 37°C. The following para-
meters were identical in all groups: (1) the route of
delivery was exclusively antegrade; (2) delivery was
intermittent; (3) cardiopulmonary bypass was conduct-
ed in active normothermia (37°C); and (4) a hot shot
was performed before aortic unclamping. Cardiac tro-
ponin I release indicated that intermediate lukewarm
cardioplegia provided better myocardial protection
than cold cardioplegia and warm cardioplegia provided
the best myocardial protection when compared with
cold or intermediate lukewarm cardioplegia in an un-
selected group of patients undergoing an elective first
cardiac operation and having preserved left ventricular
function. It could be assumed that myocardial rewarm-
ing caused by normothermic bypass might impair
myocardial protection in the cold and lukewarm groups.
We think this is unlikely to occur because of the short
time interval between two successive injections (aver-
age, 15 ± 3 minutes) and the fact that the ventricle was
vented. However, because we did not measure myocar-
dial temperature, we cannot disregard this hypothesis.
In the present study no significant differences in
postoperative clinical results were found among warm,
cold, and intermediate lukewarm cardiac protection
with intermittent antegrade administration, except a
rate of spontaneous return to sinus rhythm after aortic
unclamping, which increased significantly with the 3
temperatures. However, we do not know whether spon-
taneous return to sinus rhythm expressed a better
myocardial protection or whether electrical defibrilla-
tion resulted in an additional myocardial injury. A
greater rate of spontaneous return to sinus rhythm with
warm, as opposed to cold blood cardioplegia has
already been reported.15 In our series there was no sig-
nificant difference in immediate postoperative dysfunc-
tion between groups, as indicated by the similar need
for pharmacologic support in the three groups.
Antegrade intermittent warm and cold cardioplegia
have already been compared in several studies.
Calafiore and colleagues,16 in a nonrandomized trial,
showed that warm cardioplegia provided better clinical
outcomes. Pelletier and colleagues15 showed that there
was no difference in clinical outcome, but that cardiac
troponin T release and CK-MB mass concentration
were lower in the warm group, suggesting better
myocardial protection. Mezzetti and colleagues17
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showed that warm cardioplegia protects the myocardi-
um from ischemia-reperfusion injury better than cold
cardioplegia. Conversely, Landymore and colleagues18
showed equivalent results with both techniques. With
respect to cardiac troponin I release, our data suggest
that warm cardioplegia provided better myocardial pro-
tection than cold cardioplegia.
Interrupting warm blood cardioplegia is likely to lead
to myocardial ischemia. Because it is often necessary
to interrupt the infusion of cardioplegic solution to
improve visualization of the surgical field, several stud-
ies have been performed to determine the maximum
time of interruption. Yasuda and colleagues11 showed
that a 10-minute interruption was safe, whereas a 20-
minute interruption caused cumulative ischemic injury
in normal dog hearts. Lichtenstein and colleagues12
showed that repeated interruptions of up to 13 minutes
were unlikely to lead to adverse clinical results. For
technical reasons, 4 of our patients from the warm
group had an interruption of more than 20 minutes.
Both the clinical outcome and cardiac troponin I
release established that there was no adverse effect with
one interruption of up to 23 minutes. Should more than
one long interruption be needed, we think it wise to
interrupt the procedure to allow another infusion.
The antegrade route of delivery may be impaired by
coronary occlusions, whereas the retrograde route may
be inhomogeneous. The combined route of delivery
requires another set of tubing on the operating table to
switch back and forth from one type of perfusion to the
other. Using this technique could be cumbersome, con-
fusing, and more time consuming while the aorta is
crossclamped.19 Our study confirmed the data from
others16 stating that the antegrade route of delivery ap-
pears sufficient for most patients. The combined route
of delivery should be limited to select patients (eg,
acute coronary occlusion or redo operations).
In terms of efficacy intermediate lukewarm cardio-
plegia appears to situate itself halfway between cold
and warm cardioplegia. Cardiac troponin I release was
significantly lower in the lukewarm group than in the
cold group but significantly higher in the lukewarm
group than in the warm group. Therefore intermittent
antegrade lukewarm cardioplegia is a safe and effica-
cious method of myocardial protection with proven
advantages when compared with cold blood cardiople-
gia in elective myocardial revascularization in patients
with preserved ventricular function. Under these condi-
tions, intermittent antegrade warm cardioplegia provid-
ed the best myocardial protection.
Two patients (1.5%) had a postoperative stroke, as is
the average in published data. Our study did not con-
firm the adverse effect of normothermic cardiopul-
monary bypass on neurologic outcome, as reported by
Martin and colleagues20 and denied by Engelman and
colleagues.21
Conclusions
Intermittent antegrade intermediate lukewarm blood
cardioplegia is appropriate and clinically safe. The
release of cardiac troponin I suggests that intermediate
lukewarm cardioplegia improved protection in low-risk
patients when compared with cold blood cardioplegia.
Conversely, cardiac troponin I release suggests that
lukewarm cardioplegia is less effective for myocardial
protection than warm cardioplegia. We therefore recom-
mend the use of warm cardioplegia in low-risk patients.
We thank Nancy Richardson-Peuteuil for her editorial
assistance.
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